Covid-19 Additional Guidance


In the current pandemic situation, we know that trial participants may have concerns or questions about their trial treatment and attending follow-up appointments.  We have provided some general guidance below. However, your study doctor or nurse will be best placed to advise on your individual circumstances and the services available at your local hospital.  If they make any additional recommendations, you should follow these.

Attending follow-up appointments

Some RAMPART participants will be affected by recent NHS recommendations due to coronavirus (COVID-19). The current recommendation is that the following groups of individuals should self-isolate and are strongly advised to stay at home at all times and avoid face-to-face contact for at least the next 12 weeks:

  • People having immunotherapy or other continuing antibody treatments for cancer
  • People on immunosuppression therapies sufficient to significantly increase risk of infection (such as steroids)

If you have received immunotherapy within the last 3 months in the RAMPART trial (either Durvalumab or a combination of Durvalumab and Tremelimumab) or are currently receiving steroid treatment, you are advised to follow these recommendations. Alternative arrangements, including consultations by telephone may be available locally and your site will inform you.

We hope that you all stay well. We will be monitoring the situation continuously and will post any updates via our website.


Thank you for taking the time to read this information.